Table 1.
Participant characteristics
| Total N = 199 |
GLA-300 N = 104 |
IDEG-100 N = 95 |
p value | |
|---|---|---|---|---|
| Age years | 42.6 ± 13.4 | 43.5 ± 14.3 | 41.7 ± 12.3 | 0.3500 |
| Women, n (%) | 100 ± 50.3 | 46 ± 44.2 | 54 ± 56.8 | 0.0755 |
| BMI, kg/m2 | 26.0 ± 3.8 | 26.2 ± 4.0 | 25.7 ± 3.6 | 0.4425 |
| Time since T1D diagnosis, years | 18.4 ± 10.4 | 16.8 ± 10.1 | 20.2 ± 10.5 | 0.0218 |
| Comorbidities Associated to T1D, n (%) | 99.0 ± 49.7 | 45 ± 43.3 | 54 ± 56.8 | 0.0558 |
| Dyslipidemia | 47 ± 23.6 | 23 ± 22.1 | 24 ± 25.3 | 0.6015 |
| Hypertension | 24 ± 12.1 | 14 ± 13.5 | 10 ± 10.5 | 0.5254 |
| Retinopathy | 41 ± 20.6 | 15 ± 14.4 | 26 ± 27.4 | 0.0241 |
| Nephropathy | 12 ± 6.0 | 5 ± 4.8 | 7 ± 7.4 | 0.4485 |
| Hypothyroidism | 19 ± 9.5 | 9 ± 8.7 | 10 ± 10.5 | 0.6535 |
| Total daily insulin dose, U/kg/day | 0.6 ± 0.2 | 0.7 ± 0.2 | 0.6 ± 0.2 | 0.1456 |
| Fast-acting insulin, n (%) | ||||
| Lispro (Humalog®) | 51 2 ± 5.6 | 23 ± 22.1 | 28 ± 29.5 | 0.5310 |
| Aspart (Novorapid®) | 106 ± 53.3 | 56 ± 53.8 | 50 ± 52.6 | |
| Glulisina (Apidra®) | 36 ± 18.1 | 22 ± 21.2 | 14 ± 14.7 | |
| Regular (Actrapid®, Humulina regular®) | 6 ± 3.0 | 3 ± 2.9 | 3 ± 3.2 | |
| Basal insulin, n (%) | ||||
| Detemir (Levemir®) | 18 ± 9.0 | 7 ± 6.7 | 11 ± 11.6 | 0.2758 |
| Glargine 100 U/ml (Lantus®) | 180 ± 90.5 | 97 ± 93.3 | 83 ± 87.4 | |
| Glargine 100 U/ml (Abasaglar®) | 1 ± 0.5 | 0 | 1 ± 1.1 |
Data are mean ± SD unless otherwise stated
BMI: body mass index; T1D, type 1 diabetes